Colorimetric Assessment of BCR-ABL1 Transcripts in Clinical Samples Via Gold Nanoprobes

Gold nanoparticles functionalized with thiolated oligonucleotides (Au-nanoprobes) have been used in a range of applications for the detection of bioanalytes of interest, from ions to proteins and DNA targets. These detection strategies are based on the unique optical properties of gold nanoparticles, in particular, the intense color that is subject to modulation by modification of the medium dieletric. Au-nanoprobes have been applied for the detection and characterization of specific DNA sequences of interest, namely pathogens and disease biomarkers. Nevertheless, despite its relevance, only a few reports exist on the detection of RNA targets. Among these strategies, the colorimetric detection of DNA has been proven to work for several different targets in controlled samples but demonstration in real clinical bioanalysis has been elusive. Here, we used a colorimetric method based on Au-nanoprobes for the direct detection of the e14a2 BCR-ABL fusion transcript in myeloid leukemia patient samples without the need for retro-transcription. Au-nanoprobes directly assessed total RNA from 38 clinical samples, and results were validated against reverse transcription-nested polymerase chain reaction (RT-nested PCR) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The colorimetric Au-nanoprobe assay is a simple yet reliable strategy to scrutinize myeloid leukemia patients at diagnosis and evaluate progression, with obvious advantages in terms of time and cost, particularly in low- to medium-income countries where molecular screening is not routinely feasible. Graphical abstract Gold nanoprobe for colorimetric detection of BCR-ABL1 fusion transcripts originating from the Philadelphia chromosome.

Pesquisa de Sequências do Cromossoma Y em Indivíduos com Síndroma de Turner

O síndroma de Turner (TS) tem sido descrito em associação com diversas anomalias dos cromossomas sexuais. Embora a maioria dos individuos com TS não apresentem evidência citogenética de sequências do cromossoma Y, diferentes autores consideram que algumas doentes com TS podem possuir uma linha celular minoritária contendo material do cromossoma Y, que não é detectada pela análise citogenética convencional. A identificação de moisacismos minoritários ou subrepresentados contendo o cromossoma Y é de importância fundamental em termos clínicos devido ao risco aumentado que estas doentes possuem para desenvolvimento de gonadoblastoma. No presente estudo procedeu-se à análise citogenética convencional de linfócitos de sangue periférico obtidos de 22 doentes com TS. Destas doentes, doze possuíam cariotipo 45,X, em sete foram detectados mosaicos com ou sem anomalias estruturais do cromossoma X e nas restantes três foram identificados os seguintes cariotipos: 46,X,i (X)(q10); 46,X,+mar/47,X,idic(Y),+mar e 45,X/46,X,+r. Os estudos moleculares foram realizados em DNA genómico obtido a partir de linfócitos de sangue periférico e de células de mucosa bucal, dois tecidos que derivam de folhetos embrionários diferentes, respectivamente, mesoderme e ectoderme. A pesquisa de moisacismos minoritários envolvendo o cromossoma Y foi efectuada por PCR simples e PCR nested para os seguintes loci específicos do cromossoma Y: SRY (sex determining region Y), TSPY (testis specific protein Y encoded), DYZ3 (locus centromérico) e DAZ1 (deleted in azoospermia). O uso de STSs localizados nos braços curto e longo do cromossoma Y permitiu a caracterização de um idic (Y)e de um cromossoma em anel, detectados em duas das doentes estudadas. A eleveda sensibilidade da PCR nested (1 célila masculina/125 000 células femininas) permitiu excluir a presença de moisacismos minoritários do Y em 20 das 22 doentes com TS. Na doente com um idic(Y) a análise por PCR simples foi posistiva para todos os loci estudados com excepção da região heterocromática. Este resultado permitiu identificar o ponto de quebra no braço longo entre sY158 e sY159, tendo-se confirmado por hibridação in situ de fluorescência (FISH), a duplicação da eurocromatina do braço longo, centrómero e braço curto do cromossoma Y. A caracterização do cromossoma em anel, detectado num das doentes com TS só foi possível por FISH e por PCR. Neste cromossoma, derivado de Y, foi detectada, no braço curto, a delecção da região pseudoautossómica 1 (PARY1)e, no braço longo, a delecção dos intervalos 6 e 7. Contudo, o referido cromossoma foi positivo para os loci SRY, RPS4Y, AMGY, TSPY localizados no braço curto, DYZ3 (centrómero) e, sY85, DFFRY, GY6, sY87, sY113, sY119, sY122, sY126 e RBMY1 localizados no braço longo do cromossoma Y. Este estudo permitiu, assim, excluir a presença de moisacismos minoritários do cromossoma Y em dois tecidos obtidos de 20 doentes com TS, e caracterizar por FISH e análise molecular, um idic(Y) e um cromossoma em anel, em que a natureza deste último não tinha sido identificada por análise citogenética convencional. O risco elevado de desenvolvimento de gonadoblastoma nos indivíduos com TS que possuem sequências do cromossoma Y justifica a aplicação de FISH e PCR para a caracterização de cromossomas marcadores e a utilização de PCR nested para a detecção de moisacismos minoritários do Y sempre que o material deste cromossoma não seja detectado pela análise citogenética convencional em doentes com cariotipo 45,X e/ou virilização.

The HIF1A Functional Genetic Polymorphism at Locus +1772 Associates with Progression to Metastatic Prostate Cancer and Refractoriness to Hormonal Castration

The hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour. In this study we sought to evaluate the association of a functional genetic polymorphism in HIF1A with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT). The HIF1A +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk. Our results showed that patients under ADT carrying the HIF1A +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1-3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2-16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95%CI, 0.7-1.2). The HIF1A +1772 genetic polymorphism predicts a more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance. Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT.

The HIF1A Functional Genetic Polymorphism at Locus +1772 Associates with Progression to Metastatic Prostate Cancer and Refractoriness to Hormonal Castration

The hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour. In this study we sought to evaluate the association of a functional genetic polymorphism in HIF1A with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT). The HIF1A +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk. Our results showed that patients under ADT carrying the HIF1A +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1-3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2-16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95%CI, 0.7-1.2). The HIF1A +1772 genetic polymorphism predicts a more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance. Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT.